Over the past few weeks, one "clinical stage" pharma firm after another has seen its stock price rise and plummet on rumors about who has the most likely Ebola vaccine.
I'm not taking you on any wild rides like that. Instead, check out this solid big-cap company that's gearing up for a major Ebola drug trial.
Now, before the crowd notices, let's take a look - this is not your typical "Ebola stock"...
Over the past few weeks, one "clinical stage" pharma firm after another has seen its stock price rise and plummet on rumors about who has the most likely Ebola vaccine.
I'm not taking you on any wild rides like that. Instead, check out this solid big-cap company that's gearing up for a major Ebola drug trial.
Now, before the crowd notices, let's take a look - this is not your typical "Ebola stock"...
For weeks, investors have been chasing one "Ebola stock" after another, hoping to find the company with a cure for the disease.
But these investors are going about it all wrong. Instead of finding sound investments, they're just chasing headlines.
The number of companies racing to find an Ebola treatment is increasing. All drugs remain in the testing stage, but that hasn't stopped investors from piling into these "Ebola stocks."
Chimerix (Nasdaq: CMRX) climbed 5% Monday on reports that the Ebola patient in Dallas is being treated with its drug, brincidofovir.
Tekmira Pharma (Nasdaq: TKMR) stock surged more than 25% to $26.50 Wednesday after the CDC confirmed Tuesday the first Ebola diagnosis in the United States - and the first outside of Africa.
But just how close is Tekmira to getting approval for an Ebola treatment?
Here's a closer look at whether the Tekmira vaccine is the answer everyone hopes it is...
The first U.S. case of the deadly Ebola virus has been confirmed in a patient in Dallas, Texas, and the news sent "Ebola stocks" - the companies racing to get approval for treatment - up as much as 20% in after-hours trading Tuesday.
But instead of trying to guess which company is going to come through with a cure, I recommend you concentrate on companies making the best medical testing, diagnosis, and drug delivery systems.
Like this one – it’s going to power sharply higher in the next 12 months…
